Department of Pharmaceutical Health Outcomes and Policy
Rajender Aparasu, Ph.D., FAPhA, Chair and Professor
The Department of Pharmaceutical Health Outcomes and Policy consists of nine faculty members. In addition to providing educational component in the professional PharmD program, the Department offers graduate education programs leading to Master of Science and Doctor of Philosophy degrees in Pharmaceutical Health Outcomes and Policy. The graduate degree prepares students for research and leadership positions in pharmaceutical industry, clinical research organizations, academia, and state and Federal agencies.
The division houses the Institute for Community Health, an interdisciplinary research structure of federally funded investigators that address the Institute of Medicine's focus on community health initiatives through the collaboration of scientists and health professionals, agencies and institutions of higher learning in the Texas Medical Center. The faculty members in the department conduct research and quality initiatives to improve patient outcomes, practice, and policy related to medication, pharmacist services, and health care systems.
Our vision is to be a nationally recognized department in pharmaceutical health outcomes and policy.
Our mission is to provide education, conduct research, and offer services in pharmaceutical health outcomes and policy with an impact on the region and the nation.
- Societal impact
To achieve the mission, the department will:
1. Provide educational programs to train professional and graduate students with leadership potential:
i. Prepare doctoral level (Ph.D.) research scholars in pharmaceutical health outcomes and policy
ii. Prepare professional pharmacy (Pharm.D.) students in the areas of pharmacy administration, pharmaceutical health outcomes, and policy
2. Conduct pharmaceutical health outcomes and policy research that will benefit the community
i. Grow extramural research support
ii. Enhance scientific productivity through collaboration
3. Provide leadership, service and expertise to the community in the areas of pharmaceutical health outcomes and policy.
i. Increase community engagement
ii. Improve visibility of the department